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Available online 29 October 2016Background:We aimed to compare head-to-head the diagnostic and prognostic capabilities of galectin-3, soluble
ST2 (sST2) and B-type natriuretic peptide (BNP) for heart failure (HF) in an emergency setting.
Methods:We studied 251 consecutive patients with dyspnoea as a chief compliant presenting to an emergency
department. The diagnosis of HF was based on the Framingham score for HF plus echocardiographic evidence
of systolic or diastolic dysfunction. All-cause mortality was assessed at one year. Plasma concentrations of
galectin-3 and BNPweremeasuredwith two commercially available assays fromAbbott Diagnostics, plasma con-
centrations of sST2 were quantiﬁed with the Presage ST2 assay. The diagnostic and prognostic accuracies of
galectin-3, sST2 and BNP were assessed by receiver operating characteristic (ROC) curve analysis.
Results: Of the 251 patients, 137 had dyspnoea attributable to acute HF and 114 had dyspnoea attributable to
other reasons. BNP had a higher area under the curve (AUC) for the diagnosis of HF (0.92; 95% CI, 0.87–0.95)
than galectin-3 (0.57; 95% CI, 0.51–0.64) and sST2 (0.63; 95% CI, 0.56–0.69). Of the 137 patients with acute HF,
41 died and 96 survived during follow up. The AUC of BNP for the prediction of one-year all-cause mortality in
HF patients (0.72; 95% CI, 0.63–0.79) was not different from the AUCs of galectin-3 (0.70; 95% CI, 0.62–0.78)
and sST2 (0.75; 95% CI, 0.67–0.82).
Conclusions: In this study, galectin-3, sST2 and BNP were equally useful for the prediction of one-year all-cause
mortality in patients with acute HF. However, in contrast to BNP, galectin-3 and sST2 were not useful as an aid
in the diagnosis of acute HF in short of breath patients presenting to an emergency department.








The proteins galectin-3 and soluble ST2 (sST2) are currently gaining
mounting interest as candidate biomarkers in cardiac disease [1].
Galectin-3 is a uniquemember of chimera type galectins and is involved
in a large number of disease processes [1,2]. Galectin-3 participates
in cell adhesion, activation, proliferation, apoptosis aswell as cell migra-
tion [1–3]. It plays an important role in cancer and inﬂammation [1–4].-type natriuretic peptide; CI,
stimated glomerular ﬁltration
ure; HFpEF, heart failure with
ced ejection fraction; LVEF, left
pro-B-type natriuretic peptide;
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. This is an open access article underEven in the pathophysiology of cardiac disease, galectin-3 is thought to
play a role through inﬂammation and ﬁbrosis [1,5,6]. ST2 is an interleu-
kin-1 receptor family member with transmembrane (ST2L) and soluble
isoforms (sST2) [1,7]. sST2 is believed to function as a “decoy” receptor
for IL-33, inhibiting the effects of IL-33/ST2L signaling [1,7]. Blood
concentrations of sST2 are signiﬁcantly increased, e.g., in inﬂammato-
ry/infectious diseases, in cancer and in cardiac disease [1,7]. As a conse-
quence, increased galectin-3 plasma concentrations and increased sST2
plasma concentrations are not considered speciﬁc for a distinct medical
condition [1,8].
Based on promising data from the literature, the biomarker galectin-
3 and sST2 have been included in the 2013 ACCF/AHA guideline for the
purpose of additive risk stratiﬁcation of patients with acute and chronic
heart failure (HF) [5]. However, it remains unclear whether galectin-3
may be useful as an aid for the diagnosis of HF, especially when using
a novel chemiluminescentmicroparticle immunoassay for use in clinical
routine on a fully-automated platform (Abbott Laboratories). In addi-
tion, it is not establishedwhether galectin-3 and sST2 provide compara-
ble diagnostic and prognostic value in acute HF. Thus, we aimed tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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galectin-3, sST2 and B-type natriuretic peptide (BNP) for HF in an emer-
gency setting using assays approved by the Food and Drug Administra-
tion (FDA).
2. Methods
2.1. Study design and patients
The present evaluation is a post hoc analysis of our previously de-
scribed study cohort [9,10]. In brief, 251 consecutive patients consulting
the emergency department of the St. John of God Hospital Linz, Austria
with dyspnoea as a chief compliant were prospectively studied to com-
pare the diagnostic accuracies of BNP and amino terminal pro-B-type
natriuretic peptide (NT-proBNP) for acute HF in an emergency setting,
and to demonstrate the capability of both analytes as prognostic
markers [9]. Comprehensive information on the demographic and
clinical characteristics of the study participants is given in the previous
publications on this study cohort [9,10].
The study protocol was approved by the local ethics committee in
accordance to the Declaration of Helsinki. All study participants gave in-
formed consent. The study was performed and described according to
the criteria suggested by the standards for reporting of diagnostic accu-
racy (STARD) initiative [9].
2.2. Echocardiography
All 251 study participants underwent echocardiography within
three days after the patients'ﬁrst examination in the emergency depart-
ment [9]. Left ventricular ejection fraction (LVEF) was measured by the
quantitative two dimensional (biplane Simpson)method. Patients were
deﬁned as having systolic dysfunction if their LVEF was ≤50%. Patients
with an LVEF N50% were further examined for diastolic dysfunction.
Each of the patients with an LVEF N50% underwent pulsed wave Dopp-
ler examination of mitral inﬂowbefore and during Valsalvamanoeuvre.
Diastolic dysfunction was categorized according to the progression of
diastolic dysfunction as normal; mild (grade 1), deﬁned as impaired re-
laxation without evidence of increased ﬁlling pressures; moderate
(grade 2), deﬁned as impaired relaxation associated with moderately
increased ﬁlling pressures or pseudonormal ﬁlling; and severe (grade
3 and 4), deﬁned as reversible restrictive or ﬁxed restrictive patterns.
2.3. Diagnosis and classiﬁcation of HF
The diagnosis of acuteHFwas based on the Framingham score for HF
plus echocardiographic evidence of systolic or diastolic dysfunction [9].
For the diagnosis of HF both had to be present: Framingham HF score
with twomajor or onemajor and twominor criteria [11]; and evidence
of systolic or diastolic dysfunction as determined by echocardiography.
Patients with HF and a LVEF b50% were considered having HF with
reduced ejection fraction (HFrEF), patients with HF and a LVEF N50%
were classiﬁed as sufferingHFwith preserved ejection fraction (HFpEF).
For the attending physicians and cardiologists, BNP plasma concen-
trations were available in the medical records only after the patients
had been completely clinically evaluated and classiﬁed for the purpose
of the study.
2.4. Biomarker measurement
During the initial patient examination in our emergency depart-
ment, blood samples were collected for the measurement of BNP con-
centrations and were analysed within the next 4 h by a commercially
available microparticle enzyme immunoassay assay on an AxSYM
analyser (Abbott Laboratories) [9]. Several aliquots of these EDTA plas-
ma samples were stored at−80 °C for further analyses. Routine labora-
tory parameters (such as hemoglobin and creatinine) were determinedas previously described [9]. Estimated glomerular ﬁltration rate (eGFR)
was calculated with the MDRD (Modiﬁcation of Diet in Renal Disease)
formula: eGFR = 186 × (serum creatinine [mg/dL]) − 1.154 × (age
[years]) − 0.203 × (0.742 if female) × (1.210 if African-American)
[12]. The eGFR results were dichotomized according to the 60 mL/min
cut-off value for the present work.
One frozen aliquot was used for the determination of galectin-3 and
sST2, which were the target parameters for the present post hoc analy-
sis. All 251 plasma samples were measured in one batch for both
analytes in August 2015. We measured galectin-3 concentrations with
a chemiluminescent microparticle immunoassay on an ARCHITECT
i2000SR analyser (Abbott Laboratories) and sST2 concentrations with
the Presage ST2 enzyme-linked immunosorbent assay (Critical Diagnos-
tics) on a BEP 2000 instrument (SiemensMedical Diagnostics) as stated
elsewhere [8,13,14].
The analytical characteristics of both assays have been published
previously [1,13–17]. According to the package insert, the Abbott
galectin-3 assay has a measurement range of 4–114 ng/mL [1,8], and
in our laboratory, we found a within-run coefﬁcient of variation (CV)
of 3.6% and a total CV of 4.9% at a mean concentration of 16 ng/mL, a
within-run CV of 1.8% and a total CV of 2.6% at a mean concentration
of 22 ng/mL, and a within-run CV of 2.8% and a total CV of 4.5% at a
mean concentration of 32 ng/mL [8]. The Presage ST2 assay has a mea-
surement range of 2.8–180ng/mL (based on a 45-fold dilution of patient
samples) [8,14], and in our laboratory, we found awithin-run CV of 2.4%
and a total CV of 4.0% at amean concentration of 11 ng/mL, awithin-run
CV of 2.0% and a total CV of 3.9% at a mean concentration of 87 ng/mL,
and a within-run CV of 2.2% and a total CV of 3.9% at a mean concentra-
tion of 140 ng/mL [8].
The assays for measurement of BNP, galectin-3 and sST2 used in this
study have been approved by the FDA for use in clinical routine.
2.5. Outcome assessment
The endpoint of the present investigation was deﬁned as all-cause
mortality, and the study participants were followed up for 365 days
from the time they presented to the emergency department. Mortality
datawere obtained from theAustrianCentral Ofﬁce of Civil Registration.
All 251 patients received follow-up.
2.6. Statistical analysis
Data were statistically analysed with the SPSS 13.0 software (SPSS
Inc.), the MedCalc 13.0.0.0 package (MedCalc Software). Comparisons
between the patients groups were performed with the chi-square test
and theMann-WhitneyU test as appropriate. To determine thediagnos-
tic and prognostic accuracies of BNP, galectin-3, and sST2 for HF, receiv-
er operating characteristic (ROC) plots were analysed, and areas under
the curve (AUCs) were calculated for all three analytes. In addition, lo-
gistic regression analyses were used to assess combined biomarker
models for ROC curve analyses. AUCs were compared to each other ac-
cording to the method by Hanley and McNeil [18]. Logistic regression
analyses were also performed to determine whether the biomarker
plasma concentrations were independent diagnostic markers for acute
HF. Furthermore, Cox proportional-hazards regression analysiswas per-
formed to determine whether the biomarker plasma concentrations
were independent prognostic markers in acute HF. Obtained p values
were not adjusted for multiple comparisons and are, thus, descriptive
only.
3. Results
3.1. Diagnostic accuracy of galectin-3 and sST2 for acute HF
Of the 251 patients with dyspnoea as a chief compliant, 137 patients
were classiﬁed as having dyspnoea attributable to acute HF, and 114
Table 1
Characteristics of patients with acute dyspnoea according to HF classiﬁcation (n = 251).
Variables HF no HF p valuea
(n = 137) (n = 114)
General demographic data
Patients' age [years] 76 (69–82) 69 (58–78) b0.001
Male gender 128 (93%) 106 (93%) 0.888
Arterial hypertension 86 (63%) 55 (48%) 0.021
Diabetes mellitus 39 (29%) 19 (17%) 0.027
Atrial ﬁbrillation 65 (47%) 18 (16%) b0.001
Known coronary artery disease 81 (59%) 36 (32%) b0.001
History of HF 65 (47%) 10 (9%) b0.001
Speciﬁc measures (obtained in the
emergency department)
Body mass index [kg/m2] 26 (24–29) 26 (23−30) 0.628
Systolic blood pressure [mm Hg] 135 (113–160) 140 (120–161) 0.073
Diastolic blood pressure [mm Hg] 80 (70–90) 80 (70–91) 0.178
Heart rate [beats/min] 86 (75–110) 90 (75–115) 0.756
Symptoms of HF (ascertained in the
emergency department)
Dyspnoea on exertion 137 (100%) 114 (100%) NA
Orthopnea 28 (20%) 11 (10%) 0.019
Paroxysmal nocturnal dyspnoea 53 (39%) 22 (19%) 0.001
Nocturnal cough 50 (37%) 22 (19%) 0.003
Signs of HF (ascertained in the
emergency department)
Jugular venous distension 38 (28%) 4 (4%) b0.001
Pulmonary rales 44 (32%) 8 (7%) b0.001
Third heart sound 22 (16%) 2 (2%) b0.001
Peripheral oedema 40 (29%) 13 (11%) 0.001
Framingham score for HF
Classiﬁcation positive 137 (100%) 7 (6%) NA
Major criteria [points] 2 (1–3) 0 (0–1) NA
Minor criteria [points] 2 (1–3) 1 (1–2) NA
NYHA classiﬁcation (ascertained
in the emergency department)
NYHA I 0 (0%) 10 (9%) NA
NYHA II 59 (43%) 0 (0%) NA
NYHA III 53 (38%) 0 (0%) NA
NYHA IV 25 (18%) 0 (0%) NA
Echocardiographic data (obtained
within three days after presentation
in the emergency dept.)
LVEF [%] 40 (28–48) 59 (55–62) b0.001
Normal function 0 (0%) 43 (38%)
Diastolic dysfunction 21 (15%) 53 (46%) b0.001
Systolic dysfunction 116 (85%) 18 (16%)
Drug therapy
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sons. Table 1 details the features of the study cohort.
BNP had a higher AUC for the diagnosis of HF (0.92; 95% CI, 0.87–
0.95) than galectin-3 (0.57; 95% CI, 0.51–0.64) and sST2 (0.63; 95% CI,
0.56–0.69) as shown in Fig. 1. Galectin-3 did not add to the diagnostic
capability of BNP (AUC of BNP vs. AUC of combined biomarker model
BNP & galectin-3; difference of AUCs, 0.00; p = 0.850; Supplementary
Table 1), and similarly sST2 did not add to the diagnostic capability of
BNP (AUC of BNP vs. AUC of combined biomarker model BNP & sST2;
difference of AUCs, 0.00; p = 0.970; Supplementary Table 1). Cut-off
values with the highest diagnostic accuracies were 295 ng/L for BNP
(sensitivity, 80%; speciﬁcity, 86%), 25.9 ng/mL for galectin-3 (sensitivity,
41%; speciﬁcity, 75%) and 26.5 ng/mL for sST2 (sensitivity, 76%; speciﬁc-
ity, 49%) as speciﬁed in Table 2. These cut-off valueswere used for logis-
tic regression analysis to demonstrate the diagnostic value of increased
BNP, galectin-3 and sST2 plasma concentrations for acute HF with and
without consideration of clinical variables available at the emergency
department as shown in Table 3. In contrast to BNP, the biomarkers
galectin-3 and sST2 were not independently associated with the diag-
nosis of acute HF.
In a secondary analysis we constructed separate ROCplots for the di-
agnosis of HFrEF (i.e., 116 patients with dyspnoea attributable to HFrEF
vs. 114 patients with dyspnoea caused by other reasons) and HFpEF
(i.e., 21 patients with dyspnoea attributable to HFpEF vs. 114 patients
with dyspnoea caused by other reasons) as shown in Supplementary
Fig. 1. The respective results were similar to those detailed in the previ-
ous paragraph in that the AUCs of BNP were higher than those of
galectin-3 and sST2.
In another secondary analysis we evaluated the diagnostic capabili-
ties of BNP, galectin-3 and sST2 for HF patients with impaired eGFR.
The AUCs of the three biomarkers for the diagnosis of HF with an
eGFR b60 mL/min/1.73 m2 (i.e., 39 patients with dyspnoea attributable
to HFwith an eGFR b60mL/min/1.73m2 vs. 114 patientswith dyspnoea
caused by other reasons) were 0.93 for BNP (95% CI, 0.88–0.97), 0.83 for
galectin-3 (95% CI, 0.77–0.89) and 0.74 for sST2 (95% CI, 0.67–0.81). The
AUCs of the three biomarkers for the diagnosis of HF with an eGFR N60
mL/min/1.73m2 (i.e., 98 patients with dyspnoea attributable to HFwith
an eGFR N60mL/min/1.73m2 vs. 114 patients with dyspnoea caused by
other reasons)were 0.91 for BNP (95% CI, 0.86–0.95), 0.53 for galectin-3
(95% CI, 0.46–0.60) and 0.58 for sST2 (95% CI, 0.51–0.65).(recorded at hospital discharge)
Angiotensin converting enzyme
inhibitors
98 (72%) 23 (20%) b0.001
Angiotensin receptor blockers 9 (7%) 8 (7%) 0.888
Calcium antagonists 22 (16%) 15 (13%) 0.519
Beta-blockers 66 (48%) 20 (18%) b0.001
Digitalis 39 (29%) 7 (6%) b0.001
Diuretics 111 (81%) 42 (37%) b0.001
Amiodarone 15 (11%) 5 (4%) 0.056
Biochemical markers (measured
from blood samples collected in
the emergency department)
Hemoglobin [g/dL] 13.6 (12.3–15.0) 14.1 (13.1–15.1) 0.108
Creatinine [mg/dL] 0.9 (0.7–1.3) 0.8 (0.7–1.0) 0.006
eGFR b 60 mL/min/1.73 m2 39 (29%) 17 (15%) 0.010
BNP [ng/L] 792 (363–1714) 65 (10–196) b0.001
Galectin-3 [ng/mL] 22 (17–33) 19 (15–27) 0.047
sST2 [ng/mL] 40 (27–69) 29 (20–54) 0.001
Data are presented as median (25th–75th percentiles) or number (%).
Abbreviations: BNP, B-type natriuretic peptide; eGFR, estimated glomerularﬁltration rate;
HF, heart failure; LVEF, left ventricular ejection fraction; NA, not applicable; NYHA, New
York Heart Association; sST2, soluble isoformof the interleukin-1 receptor familymember
ST2.
a Comparisons between patientswithHF (n=137) and patientswithout HF (n=114)
were performed with the chi-square test for the categorical variables and with the non-
parametric Mann–Whitney U test for the continuous variables (respective p values were
not adjusted for multiple comparisons, and are therefore descriptive only).3.2. Prognostic accuracy of galectin-3 and sST2 for acute HF
Of the 137 patients with HF, 41 died and 96 survived during follow
up. The median survival of the decedents was 108 days (range, 3–
342 days). The baseline patient characteristics for survivors and
decedents are shown in Table 4.
The AUC of BNP for the prediction of one-year all-cause mortality in
HF (0.72; 95%CI, 0.63–0.79)wasnot different from theAUCs of galectin-
3 (0.70; 95% CI, 0.62–0.78) and of sST2 (0.75; 95% CI, 0.67–0.82) as
shown in Fig. 2. A statistical model combining the predictive values of
the biomarkers did not improve the prognostic capabilities of each ana-
lyte (AUC of BNP vs. AUC of combined biomarkermodel BNP & galectin-
3; difference of AUCs, 0.03; p= 0.371; and AUC of galectin-3 vs. AUC of
combined biomarker model BNP & galectin-3; difference of AUCs, 0.05;
p = 0.166; AUC of BNP vs. AUC of combined biomarker model BNP &
sST2; difference of AUCs, 0.06; p = 0.083; and AUC of sST2 vs. AUC of
combined biomarker model BNP & sST2; difference of AUCs, 0.03;
p = 0.473; Supplementary Table 2). Cut-off values with the highest
prognostic accuracies were 925 ng/L for BNP (sensitivity, 68%; speciﬁc-
ity, 69%), 32.9 ng/mL for galectin-3 (sensitivity, 54%; speciﬁcity, 88%),
and 57.0 ng/mL (sensitivity, 68%; speciﬁcity, 79%) as speciﬁed in Table
5. These cut-off values were used in Cox proportional-hazards regres-
sion analyses to determine the predictive values of the biomarker plas-
ma concentrations in acute HF as detailed in Table 6. As a result, BNP,
Fig. 1. Diagnostic information of the biomarkers for HF (n = 251).
Table 3
Diagnostic value of increased BNP, galectin-3 and sST2 plasma concentrations for acute HF
with and without consideration of clinical variables available at the emergency
department.





BNP N 295 ng/L 25.0 (12.7–49.0) b0.001
Model 2c 57%
Galectin-3 N 13.4 ng/mL 1.8 (0.8–3.7) 0.136
Model 3d 64%
sST2 N 26.5 ng/mL 3.0 (1.8–5.2) b0.001
Model 4e 83%
BNP N 295 ng/L 22.9 (11.5–45.4) b0.001
Galectin-3 N 13.4 ng/mL 0.9 (0.3–2.4) 0.813
sST2 N 26.5 ng/mL 2.1 (1.1–4.4) 0.035
Model 5f 86%
BNP N 295 ng/L 10.4 (4.5–23.7) b0.001
Model 6g 79%
Galectin-3 N 13.4 ng/mL 1.1 (0.4–2.8) 0.921
Model 7h 80%
sST2 N 26.5 ng/mL 2.0 (0.9–4.1) 0.059
Model 8i 86%
BNP N 295 ng/L 9.8 (4.3–22.4) b0.001
Galectin-3 N 13.4 ng/mL 0.9 (0.3–2.7) 0.836
sST2 N 26.5 ng/mL 1.7 (0.7–3.8) 0.226
Observed frequencies: patients with dyspnoea caused by acute destabilized HF, n = 137;
patients with dyspnoea attributable to other causes, n = 114.
Abbreviations: BNP, B-type natriuretic peptide; CI, conﬁdence interval; eGFR, estimated
glomerular ﬁltration rate; HF, heart failure; sST2, soluble isoform of the interleukin-1
receptor family member ST2.
a Diagnostic accuracies are derived from the respective whole statistical model includ-
ing all independent variables simultaneously.
b Model 1: univariate logistic regression analysis with BNP alone.
c Model 2: univariate logistic regression analysis with galectin-3 alone.
d Model 3: univariate logistic regression analysis with sST2 alone.
e Model 4: mulitvariate logistic regression analysis with the three biomarkers BNP,
galectin-3 and sST2 combined.
f Model 5:multivariate logistic regression analysiswith BNP and adjustment for clinical
variables available at the emergency department (i.e. advanced age N 75 years, sex, renal
dysfunction with eGFR b 60 mL/min/1.73 m2, history of acute destabilized HF, the pres-
ence of orthopnea, paroxysmal nocturnal dyspnoea, nocturnal cough, jugular venous dis-
tension, pulmonary rales, third heart sound, and peripheral edema).
g Model 6: multivariate logistic regression analysis with galectin-3 and adjustment for
the same clinical variables as in Model 5.
h Model 7: multivariate logistic regression analysis with sST2 and adjustment for the
same clinical variables as in Model 5.
i Model 8: multivariate logistic regression analysis with the three biomarkers BNP,
161T. Mueller et al. / Clinica Chimica Acta 463 (2016) 158–164galectin-3 and sST2 were independent predictors of all-cause mortality
at one year in the patients with acute HF.
4. Discussion
The main ﬁnding of the present post hoc analysis was that BNP is
better useful for the biochemical diagnosis of acute HF in an emergency
setting than galectin-3 or sST2. For the prognosis of all-cause mortality
of patients with acute HF the three analytes seem to be equally useful.
Neither for diagnostic nor for prognostic purposes, galectin-3 or sST2
added to the value of BNP.
BNP andNT-proBNP are the golden standard biomarkers in the eval-
uation of patientswithHF [5]. In the 2013ACCF/AHA guideline, it is stat-
ed that biomarkers of myocardial ﬁbrosis, namely sST2 and galectin-3
are not only predictive of hospitalization and death in patients withTable 2











BNP [ng/L] 100a 96% 61% 75% 93% 80%
118 95%c 64% 76% 91% 81%
160 90%c 73% 80% 87% 83%
295b 80% 86% 87% 78% 83%
Galectin-3
[ng/mL]
11.5 95%c 8% 55% 56% 55%
13.4b 90%c 17% 56% 58% 57%
17.8a 70% 39% 58% 52% 56%
25.9a 41% 75% 66% 51% 56%
sST2
[ng/mL]
14.5 95%c 4% 54% 42% 54%
18.8 90%c 21% 58% 63% 59%
26.5b 76% 49% 64% 63% 64%
35.0a 60% 61% 65% 56% 60%
Abbreviations: BNP, B-type natriuretic peptide; HF, heart failure; sST2, soluble isoform of
the interleukin-1 receptor family member ST2.
a Recommended clinical decision concentrations according to the package insert of the
Abbott AxSYM BNP assay (i.e., 100 ng/L), the Abbott galectin-3 assay (i.e., 17.8 and
25.9 ng/mL) and the Presage ST2 assay (i.e., 35 ng/mL).
b Criterion concentrations corresponding to the highest diagnostic accuracy (i.e., opti-
mal cut off concentrations with minimal false negative and false positive results).
c Cut off concentrations, speciﬁcities, positive predictive values, negative predictive
values and diagnostic accuracies at ﬁxed sensitivities of 95% and 90%.
galectin-3 and sST2 and adjustment for the same clinical variables as in Model 5.HF but also additive to natriuretic peptide levels in their prognostic
value [5]. In addition, it has been proposed that strategies that combine
multiple biomarkersmay ultimately prove beneﬁcial in guidingHF ther-
apy in the future [5].
Our study evaluated whether the fully-automated Abbott galectin-3
assay would be useful as an aid for the diagnosis of HF in an emergency
setting. There is one important study also evaluating the diagnostic
value of galectin-3 for HF in dyspnoeic patients albeit using a former
enzyme-linked immunosorbent assay [19]. Although the absolute
galectin-3 concentrations between this study and ours are not directly
comparable, most probably due to the different assays used, themagni-
tude of the diagnostic value of galectin-3 was quite similar in both stud-
ies resulting in the appraisal that galectin-3 is not useful for diagnostic
purposes in the described setting. Similarly, previously published
studies indicated that sST2 lacks speciﬁcity for a certain disease group,
limiting its use as a diagnostic test [7,8,20]. Thus, our present study
strengthens indications derived from the literature by demonstrating
that both galectin-3 and sST2 are most probably not useful as an aid
for the diagnosis of HF in an emergency setting.
With respect to the value of galectin-3measurements for prognostic
purposes in HF, there are conﬂicting data in the literature [5,6,19,21,22].
Anyway, our data is not indicative that galectin-3 or sST2 would be
useful for mortality prediction in clinical practice on top of BNP in an
Table 4
Characteristics of patients with acute HF according to survival status at one year.
Variables Survivors Decedents p valuea
(n = 96) (n = 41)
General demographic data
Patients' age [years] 75 (65–80) 79 (72–83) 0.023
Male gender 90 (94%) 38 (93%) 0.817
Arterial hypertension 66 (69%) 20 (49%) 0.027
Diabetes mellitus 26 (27%) 13 (32%) 0.583
Atrial ﬁbrillation 47 (49%) 18 (44%) 0.587
Known coronary artery disease 57 (59%) 24 (59%) 0.927
History of HF 39 (41%) 26 (63%) 0.014
Speciﬁc measures (obtained in the emergency department)
Body mass index [kg/m2] 27 (25–30) 25 (23–26) b0.001
Body weight [kg] 80 (68–92) 74 (70–80) 0.024
Systolic blood pressure [mm Hg] 140 (120–160) 120 (100–140) 0.001
Diastolic blood pressure [mm Hg] 80 (70–94) 70 (63–85) 0.003
Heart rate [beats/min] 85 (75–106) 100 (78–117) 0.089
NYHA classiﬁcation (ascertained in the emergency department)
NYHA II n = 48 (50%) n = 11 (27%)
NYHA III n = 36 (37%) n = 17 (41%) 0.009
NYHA IV n = 12 (13%) n = 13 (32%)
Echocardiographic data (obtained within three days after presentation in the emergency dept.)
LVEF [%] 40 (30–48) 35 (20–45) 0.019
Normal function n = 0 (0%) n = 0 (0%)
Diastolic dysfunction n = 18 (19%) n = 3 (7%) 0.089
Systolic dysfunction n = 78 (81%) n = 38 (93%)
Final HF diagnosis
HFpEF n = 18 (19%) n = 3 (7%) 0.089
HFrEF n = 78 (81%) n = 38 (93%)
Variables recorded at hospital discharge
Body weight [kg] 77 (66–90) 73 (66–79) 0.035
Hospital length of stay [days] 7 (4–12) 10 (5–16) 0.107
Weight loss during hospitalization (decongestion) n = 72 (75%) n = 29 (71%) 0.603
Worsening renal function during hospitalizationb n = 13 (14%) n = 7 (17%) 0.592
Drug therapy (recorded at hospital discharge)
Angiotensin converting enzyme inhibitors n = 72 (75%) n = 26 (63%) 0.169
Angiotensin receptor blockers n = 7 (7%) n = 2 (5%) 0.602
Calcium antagonists n = 18 (19%) n = 4 (10%) 0.189
Beta-blockers n = 51 (53%) n = 15 (37%) 0.076
Digitalis n = 25 (26%) n = 14 (34%) 0.336
Diuretics n = 77 (80%) n = 34 (83%) 0.710
Amiodarone n = 10 (10%) n = 5 (12%) 0.760
Biochemical markers (measured from blood samples collected in the emergency department)
Hemoglobin [g/dL] 14.1 (12.6–15.3) 12.5 (11.3–14.5) 0.003
Creatinine [mg/dL] 0.9 (0.7–1.1) 1.2 (0.9–1.9) 0.001
eGFR b 60 mL/min/1.73 m2 21 (22%) 18 (44%) 0.009
BNP [ng/L] 668 (297–1201) 1461 (683–3197) b0.001
Galectin-3 [ng/mL] 20 (16–28) 35 (19–47) b0.001
sST2 [ng/mL] 36 (23–54) 67 (43–127) b0.001
Data are presented as median (25th–75th percentiles) or number (%).
Abbreviations: BNP, B-type natriuretic peptide; eGFR, estimated glomerular ﬁltration rate; HF, heart failure; HFpEF heart failure with preserved ejection fraction; HFrEF heart failure with
reduced ejection fraction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; sST2, soluble isoform of the interleukin-1 receptor family member ST2.
a Comparisons between survivors (n=96) and decedents (n=41)were performedwith the chi-square test for the categorical variables andwith the non-parametricMann–Whitney
U test for the continuous variables (respective p values were not adjusted for multiple comparisons, and are therefore descriptive only).
b Worsening renal function was deﬁned as an in-hospital decrease in serum creatinine ≥0.3 mg/dL compared with the value at presentation.
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proBNP) should be measured during the evaluation of (suspected)
acute HF in any case, and based on our observation that galectin-3 and
sST2 do not add markedly to the prognostic value of BNP, there is – to
our opinion – no necessity to measure galectin-3 or sST2 as a second
biomarker in clinical practice of HF evaluation in an emergency depart-
ment. On the basis of our data, we therefore cast doubt on themeaning-
fulness of a multi-marker strategy using galectin-3 and/or sST2 in
addition to natriuretic peptides for the biochemical diagnosis or prog-
nosis of HF in an emergency setting.5. Limitations
The major limitation of the present study is that this was a post hoc
evaluation of the diagnostic and prognostic capability of galectin-3 and
sST2 for acute HF. We also have to acknowledge that our study is asingle-centre study performed in a relatively small sample of predomi-
nantly male patients and may not accurately represent the general de-
mographics of patients presenting with acute HF to other institutions.
Therefore, the reproduction of our results in prospectively planned
and adequately powered studies performed in other centres would
argue for their validity.6. Conclusion
In this study, galectin-3, sST2 and BNP were equally useful for the
prediction of one-year all-cause mortality in patients with acute HF.
However, in contrast to BNP, galectin-3 and sST2 were not useful as an
aid in the diagnosis of acute HF in short of breath patients presenting
to an emergency department.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2016.10.034.
Fig. 2. Prognostic information of the biomarkers for 1-year mortality in HF patients
(n = 137).
Table 6
Prognostic value of increased BNP, galectin-3 and sST2 plasma concentrations for all-cause
mortality in HF patients with and without consideration of clinical variables.
Independent variables Risk ratio (95% CI) p value
Model 1a
BNP N 925 ng/L 3.7 (1.9–7.1) b0.001
Model 2b
Galectin-3 N 32.9 ng/mL 5.5 (3.0–10.2) b0.001
Model 3c
sST2 N 57.0 ng/mL 5.4 (2.8–10.5) b0.001
Model 4d
BNP N 925 ng/L 2.9 (1.5–5.7) 0.002
Galectin-3 N 32.9 ng/mL 3.1 (1.5–6.4) 0.002
sST2 N 57.0 ng/mL 2.6 (1.2–5.5) 0.015
Model 5e
BNP N 925 ng/L 3.9 (1.8–8.3) b0.001
Model 6f
Galectin-3 N 32.9 ng/mL 4.7 (2.2–9.9) b0.001
Model 7g
sST2 N 57.0 ng/mL 4.3 (2.1–8.7) b0.001
Model 8h
BNP N 925 ng/L 3.6 (1.6–8.3) 0.002
Galectin-3 N 32.9 ng/mL 3.0 (1.4–6.6) 0.006
sST2 N 57.0 ng/mL 2.6 (1.2–5.8) 0.017
Observed frequencies: survivors, n = 96; decedents, n = 41.
Abbreviations: BNP, B-type natriuretic peptide; CI, conﬁdence interval; eGFR, estimated
glomerular ﬁltration rate; HF, heart failure; LVEF, left ventricular ejection fraction;
NYHA, New York Heart Association; sST2, soluble isoform of the interleukin-1 receptor
family member ST2.
a Model 1: univariate Cox proportional-hazards regression analysis with BNP alone.
b Model 2: univariate Cox proportional-hazards regression analysis with galectin-3 alone.
c Model 3: univariate Cox proportional-hazards regression analysis with sST2 alone.
d Model 4: mulitvariate Cox proportional-hazards regression analysis with the three
biomarkers BNP, galectin-3 and sST2 combined.
e Model 5: multivariate Cox proportional-hazards regression analysis with BNP and
adjustment for clinical variables (i.e. advanced age N 75 years, low systolic blood
pressure b 115 mm Hg, renal dysfunction with eGFR b 60 mL/min/1.73 m2, systolic
dysfunction with LVEF b 50%, and high NYHA classes III/IV).
f Model 6: multivariate Cox proportional-hazards regression analysis with galectin-3
and adjustment for the same clinical variables as in Model 5.
g Model 7: multivariate Cox proportional-hazards regression analysis with sST2 and
adjustment for the same clinical variables as in Model 5.
h Model 8: multivariate Cox proportional-hazards regression analysis with the three
biomarkers BNP, galectin-3 and sST2 and adjustment for the same clinical variables as in
Model 5.
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BNP [ng/L] 100a 100% 5% 31% 100% 34%
925b 68% 69% 48% 84% 69%
Galectin-3
[ng/mL]
17.8a 81% 34% 34% 81% 48%
25.9a 63% 70% 47% 82% 68%
32.9b 54% 88% 65% 82% 77%
sST2 [ng/mL] 35.0a 78% 48% 39% 84% 57%
57.0b 68% 79% 58% 85% 76%
Abbreviations: BNP, B-type natriuretic peptide; HF, heart failure; sST2, soluble isoform of
the interleukin-1 receptor family member ST2.
a Recommended clinical decision concentrations according to the package insert of the
Abbott AxSYM BNP assay (i.e., 100 ng/L), the Abbott galectin-3 assay (i.e., 17.8 and
25.9 ng/mL) and the Presage ST2 assay (i.e., 35 ng/mL).
b Criterion concentrations corresponding to the highest prognostic accuracy (i.e., opti-
mal cut off concentrations with minimal false negative and false positive results).References
[1] T. Mueller, B. Dieplinger, Soluble ST2 and galectin-3: what we know and don't know
analytically, EJIFCC 27 (2016) 224–237.
[2] N.C. Henderson, T. Sethi, The regulation of inﬂammation by galectin-3, Immunol.
Rev. 2230 (2009) 160–171.
[3] L. Song, J.W. Tang, L. Owusu, M.Z. Sun, J. Wu, J. Zhang, Galectin-3 in cancer, Clin.
Chim. Acta 431 (2014) 185–191.
[4] P. Ravani, B.J. Barrett, Galectin-3 and new-onset CKD: marker or mediator? J. Am.
Soc. Nephrol. 24 (2013) 1342–1344.
[5] C.W. Yancy,M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., M.H. Drazner, G.C. Fonarow,
S.A. Geraci, T. Horwich, J.L. Januzzi, M.R. Johnson, E.K. Kasper, W.C. Levy, F.A.
Masoudi, P.E. McBride, J.J. McMurray, J.E. Mitchell, P.N. Peterson, B. Riegel, F. Sam,
L.W. Stevenson, W.H. Tang, E.J. Tsai, B.L. Wilkoff, American College of Cardiology
Foundation; American Heart Association Task Force on Practice Guidelines. 2013
ACCF/AHA guideline for the management of heart failure: a report of the American
College of Cardiology Foundation/American Heart Association task force on practice
guidelines, J. Am. Coll. Cardiol. 62 (2013) e147–e239.
[6] R.A. de Boer, L.B. Daniels, A.S. Maisel, J.L. Januzzi Jr., State of the art: newer bio-
markers in heart failure, Eur. J. Heart Fail. 17 (2015) 559–569.
[7] T. Mueller, A.S. Jaffe, Soluble ST2—analytical considerations, Am. J. Cardiol. 115
(2015) 8B–21B.
[8] T. Mueller, I. Leitner, M. Egger, M. Haltmayer, B. Dieplinger, Association of the
biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with
heart failure and other non-cardiac diseases, Clin. Chim. Acta 445 (2015) 155–160.
[9] T. Mueller, A. Gegenhuber,W. Poelz, M. Haltmayer, Diagnostic accuracy of B type na-
triuretic peptide and amino terminal proBNP in the emergency diagnosis of heart
failure, Heart 91 (2005) 606–612.
[10] A. Gegenhuber, J. Struck, B. Dieplinger, W. Poelz, R. Pacher, N.G. Morgenthaler, A.
Bergmann, M. Haltmayer, T. Mueller, Comparative evaluation of B-type natriuretic
peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-
adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute
destabilized heart failure, J. Card. Fail. 13 (2007) 42–49.
164 T. Mueller et al. / Clinica Chimica Acta 463 (2016) 158–164[11] M. Senni, C.M. Tribouilloy, R.J. Rodeheffer, S.J. Jacobsen, J.M. Evans, K.R. Bailey, M.M.
Redﬁeld, Congestive heart failure in the community: a study of all incident cases in
Olmsted County, Minnesota, in 1991, Circulation 98 (1998) 2282–2289.
[12] A.S. Levey, T. Greene, J.W. Kusek, G.J. Beck, A simpliﬁed equation to predict glomer-
ular ﬁltration rate from serum creatinine, J. Am. Soc. Nephrol. 11 (2000) A0828.
[13] T. Mueller, M. Egger, I. Leitner, C. Gabriel, M. Haltmayer, B. Dieplinger, Reference
values of galectin-3 and cardiac troponins derived from a single cohort of healthy
blood donors, Clin. Chim. Acta 456 (2016) 19–23.
[14] B. Dieplinger, J.L. Januzzi Jr., M. Steinmair, C. Gabriel, W. Poelz, M. Haltmayer, T.
Mueller, Analytical and clinical evaluation of a novel high-sensitivity assay for mea-
surement of soluble ST2 in human plasma— the presage ST2 assay, Clin. Chim. Acta
409 (2009) 33–40.
[15] W.C. Meijers, A.R. van der Velde, R.A. de Boer, The ARCHITECT galectin-3 assay: com-
parison with other automated and manual assays for the measurement of circulat-
ing galectin-3 levels in heart failure, Expert. Rev. Mol. Diagn. 14 (2014) 257–266.
[16] S.L. La'ulu, F.S. Apple, M.M. Murakami, R. Ler, W.L. Roberts, J.A. Straseski, Perfor-
mance characteristics of the ARCHITECT Galectin-3 assay, Clin. Biochem. 46
(2013) 119–122.[17] J. Lu, J.V. Snider, D.G. Grenache, Establishment of reference intervals for soluble ST2
from a United States population, Clin. Chim. Acta 411 (2010) 1825–1826.
[18] J.A. Hanley, B.J. McNeil, A method of comparing the areas under receiver operating
characteristic curves derived from the same cases, Radiology 148 (1983) 839–843.
[19] R.R. van Kimmenade, J.L. Januzzi Jr., P.T. Ellinor, U.C. Sharma, J.A. Bakker, A.F. Low, A.
Martinez, H.J. Crijns, C.A. MacRae, P.P. Menheere, Y.M. Pinto, Utility of amino-termi-
nal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of pa-
tients with acute heart failure, J. Am. Coll. Cardiol. 48 (2006) 1217–1224.
[20] B. Dieplinger, M. Egger, A. Gegenhuber, M. Haltmayer, T. Mueller, Analytical and
clinical evaluation of a rapid quantitative lateral ﬂow immunoassay for measure-
ment of soluble ST2 in human plasma, Clin. Chim. Acta 451 (2015) 310–315.
[21] E. Zamora, J. Lupón, M. de Antonio, A. Galán, M. Domingo, A. Urrutia, M. Troya, A.
Bayes-Genis, Renal function largely inﬂuences galectin-3 prognostic value in heart
failure, Int. J. Cardiol. 177 (2014) 171–177.
[22] C.E. Jackson, C. Haig, P. Welsh, J.R. Dalzell, I.K. Tsorlalis, A. McConnachie, D. Preiss,
S.D. Anker, N. Sattar, M.C. Petrie, R.S. Gardner, J.J. McMurray, The incremental prog-
nostic and clinical value of multiple novel biomarkers in heart failure, Eur. J. Heart
Fail. (2016 Apr 25), http://dx.doi.org/10.1002/ejhf.543.
